The safety and efficacy of NEUTROMAX given on the same days as myelosuppressive cytotoxic chemotherapy has not been established. In view of the sensitivity of rapidly dividing myeloid cells to myelosuppressive cytotoxic chemotherapy, its use is not recommended in the period from 24 hours before to 24 hours after chemotherapy. Possible Filgrastim interactions with other hematopoietic growth factors and cytokines have not yet been investigated in clinical trials (see Caution for Usage).